The implementation of CPOE was associated with a reduction in OEs in the prescribing phase or order entry phase of the medication-use process.

Information from this review will guide health care providers in limiting weight loss and improving performance status of cachectic patients through pharmacological therapy, with the hope that such therapy will extend patients' survival and improve their qualities of life.

No abstract

INTRODUCTION: Guanfacine (Tenex) is an alpha-2 agonist. Immediate release guanfacine has an indication for hypertension and extended release is labeled for use in Attention Deficit Hyperactivity Disorder. Recent case reports suggest a possible role in delirium and alcohol withdrawal. At Tampa General Hospital, guanfacine was added to the medication formulary for the management of ICU delirium. This medication use evaluation assessed the use of guanfacine and its associated safety and efficacy for this indication.